<DOC>
	<DOCNO>NCT00297193</DOCNO>
	<brief_summary>Transplant study patient relapse Crohn 's disease demonstrate clear intolerance toxicity conventional treatment . The purpose study determine whether potential clinical benefit hematopoietic stem cell mobilisation follow high dose immuno-ablation autologous stem cell transplantation versus hematopoietic stem cell mobilisation follow best clinical practice .</brief_summary>
	<brief_title>ASTIC Autologous Stem Cell Transplantation Crohn 's Disease</brief_title>
	<detailed_description>Open label , phase III , randomise , multicentre study compare early transplantation procedure transplantation carry protocol delay one year . The status patient undergo early HSCT evaluate one year compare undergo delayed HSCT Patients randomise : - Hematopoietic stem cell mobilisation follow , within 4 week , high dose immunoablation autologous stem cell transplantation - Hematopoietic stem cell mobilisation follow , 59 week , high dose immunoablation autologous hematopoietic stem cell transplantation All patient mobilise prior randomisation . Those receive early transplantation compare first year whose transplant delayed .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Inclusion criterion : mandatory 1 . Age 18 50 year ( Patients age 5065 participate specially approve Trial Steering Committee ) 2 . Confirmed diagnosis active Crohn 's Disease 3 . Unsatisfactory course despite 3 immunosuppressive agent ( usually azathioprine , methotrexate infliximab ) addition corticosteroid . Patients relapse disease ( i.e . &gt; 1 exacerbation/year ) despite thiopurines , methotrexate and/or infliximab maintenance therapy clear demonstration intolerance / toxicity drug . 4 . Impaired function quality life , compare population mean , least one following : 1 . IBDQ ( Appendix 6 ) 2 . European Questionnaire Life quality ( EuroQOL5D , Appendix 4 ) 3 . Impaired function Karnofsky index ( Appendix 7 ) 5 . Current problem unsuitable surgery patient risk develop short bowel syndrome . 6 . Informed consent Inclusion criterion : discretionary 1 . Wherever possible , diseased tissue accessible endoscopically objective histological study case small bowel disease extensive extend duodenum terminal ileum , participation without endoscopy allow . 2 . Smokers may enter study provide receive intensive counsel smoking . 3 . Add patient ileostomy/colostomy patient short bowel syndrome 1 . Pregnancy unwillingness use adequate contraception study 2 . Concomitant severe disease 3 . Diarrhoea due short small large bowel 4 . Infection risk thereof 5 . Significant malnutrition : Body Mass Index ( BMI ) â‰¤18 , serum albumin &lt; 20 g/l 6 . Previous poor compliance 7 . Concurrent enrolment protocol use investigational drug hematopoietic growth factor four week study entry . 8 . Lack funding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>HSCT</keyword>
	<keyword>Autologous</keyword>
	<keyword>EBMT</keyword>
	<keyword>ECCO</keyword>
</DOC>